On March 31st we celebrate World “Theragnostics Day” celebrating the day in 1941 when the first radioiodine treatment was administered by Dr. Saul Hertz at Massachusetts General Hospital.
In 2022 WARMTH is proud to host a one-webinar with experts in the field of Theragnositcs for Prostate Cancer - moderated by our President Mike Sathekge.
Our webinar will start at 13:00 CET, to see your local time click here.
|Mike Sathekge – WARMTH President
|VISION Trial in mCRPC
|Prof Oliver Sartor - USA
|"Life after VISION: Where to next ?"
|Prof Louise Emmett - AU
QA & Discussion
Prof Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990, when he finished a fellowship at the National Cancer Institute (NCI). He has published over 300 articles and book chapters and led multiple national and international clinical trials as principal investigator or co-principal investigator. In particular, he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel. He has lectured widely and, at last count, has given invited lectures in 28 countries. Now recently for 177Lu-PSMA in Prostate cancer – Lead author of the Vision trial in NEJM.
Prof Louise Emmett is the Director of Theranostics and Nuclear medicine at St Vincent’s Hospital Sydney, with a current specialty interest in the imaging and therapy of Prostate Cancer. She undertook her undergraduate medical training in Auckland, New Zealand, prior to completing her specialty training in Nuclear Medicine in Sydney and a post-specialty Nuclear Cardiology fellowship in Toronto, Canada, in 2001.